Zeteletinib
 |
2-[6-(6,7-dimethoxyquinolin-3-yl)pyridin-3-yl]-N-[3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-5-yl]acetamide
|
| CAS Number |
|
|
PubChem CID
|
|
| ChemSpider |
|
| UNII |
|
| ChEMBL |
|
| Formula |
C25H23F3N4O4
|
| Molar mass |
500.478 g·mol−1
|
| 3D model (JSmol) |
|
CC(C)(C1=NOC(=C1)NC(=O)CC2=CN=C(C=C2)C3=CN=C4C=C(C(=CC4=C3)OC)OC)C(F)(F)F
|
InChI=1S/C25H23F3N4O4/c1-24(2,25(26,27)28)21-11-23(36-32-21)31-22(33)7-14-5-6-17(29-12-14)16-8-15-9-19(34-3)20(35-4)10-18(15)30-13-16/h5-6,8-13H,7H2,1-4H3,(H,31,33)
Key:KOLQINCWMXQEOF-UHFFFAOYSA-N
|
Zeteletinib (BOS-172738, DS-5010) is an experimental anticancer medication which acts as a RET inhibitor.
See also